Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
J Glaucoma. 2014 Feb;23(2):115-8. doi: 10.1097/IJG.0b013e318265bc0b.
To report the efficacy and safety of Ahmed glaucoma valve (AGV) insertion into the ciliary sulcus in pseudophakic/aphakic patients.
A chart review was done on patients with uncontrolled glaucoma, who underwent AGV implantation with tube inserted into the ciliary sulcus. Baseline intraocular pressure (IOP) and number of medications were compared with that of postoperative follow-up visits. Surgical success was defined as last IOP <21 mm Hg and 20% reduction in IOP, without further surgery for complications or glaucoma control, and without loss of light perception. Postoperative complications were recorded.
Twenty-three eyes of 23 patients were recruited with the mean follow-up of 9 months (range, 3 to 24 mo). The mean (SD) age of patients was 49.9 (16.9) years (range, 22 to 80 years). The mean (SD) IOP (mm Hg) was reduced from 37.9 (12.4) before surgery to 16.2 (3.6) at the last follow-up visit (P<0.001). The mean (SD) number of medications was reduced from 3.3 (0.9) preoperatively to 1 (1.1) at the last follow-up (P<0.001). Success rate was 18/23 (78.6%). Complications included endophthalmitis in 1 eye, tube exposure in 1 diabetic patient, and vitreous tube occlusion in 1 eye. No case of corneal decompensation or graft failure was seen during follow-up.
Ciliary sulcus placement of the tube of AGV effectively reduces IOP and medication use in short term. It has the potential to lower corneal complications of anterior chamber tube insertion and avoids the need for pars plana vitrectomy and tube insertion in patients at higher risk of corneal decompensation.
报告睫状沟内植入 Ahmed 青光眼阀(AGV)治疗白内障/无晶状体患者青光眼的疗效和安全性。
对接受睫状沟内植入 AGV 并将引流管插入睫状沟的青光眼患者进行了病历回顾。比较了患者术前的眼压(IOP)和药物使用数量与术后随访时的眼压和药物使用数量。手术成功定义为最后眼压<21mmHg,IOP 降低 20%,无因并发症或青光眼控制而进一步手术,且无光感丧失。记录了术后并发症。
共纳入 23 例(23 只眼)患者,平均随访 9 个月(3 至 24 个月)。患者的平均(标准差)年龄为 49.9(16.9)岁(22 至 80 岁)。术前平均(标准差)IOP(mmHg)为 37.9(12.4),末次随访时为 16.2(3.6)(P<0.001)。术前平均(标准差)用药数量为 3.3(0.9),末次随访时为 1(1.1)(P<0.001)。成功率为 18/23(78.6%)。并发症包括 1 只眼眼内炎、1 例糖尿病患者引流管暴露和 1 只眼玻璃体积液管阻塞。随访期间无角膜失代偿或移植物失败病例。
睫状沟内放置 AGV 引流管可在短期内有效降低眼压和用药量。它有可能降低前房引流管插入引起的角膜并发症的风险,避免了角膜失代偿风险较高的患者需要行玻璃体切割术和管插入。